NATIONAL INSTITUTES OF HEALTH (NIH) RECOMBINANT DNA ADVISORY COMMITTEE (RAC)

114th Meeting

NIH Campus Natcher Building, Rooms E1 and E2 Bethesda, MD September 9-10, 2008 Agenda

Tuesday, September 9, 2008

1:00 PM	Call to Order and Opening Remarks Howard Federoff, M.D., Ph.D., Chair, NIH RAC		
	Not Con	Your Information tice of Meeting nflict of Interest Guidance icles of Interest	
1:05 PM	Gene Transfer Safety Assessment Board Report		
	Pro Pro	sponses to M-I-C-1 tocol List tocols Not Selected for In-Depth Review and ablic Discussion	
	RAC Reviewers:	Howard Federoff, M.D., Ph.D. Scott Strome, M.D. David Williams, M.D. John Zaia, M.D.	
1:30 PM	Discussion of Human Gene Transfer Protocol #0807-927: Phase I Translational Trial of Oncolytic Virotherapy with Recombinant Vesicular Stomatitis Virus ($rVSV(M\Delta 51)-M3$) by Hepatic Arterial Delivery in Patients with Primary Hepatocellular Carcinoma or Metastatic Colorectal Carcinoma in the Liver		
	PIs: Savio L.C. Woo, Ph.D., and Max W. Sung, M.D., Mount Sinai School of Medicine, New York, NY		
	RAC Reviewers:	Hung Fan, Ph.D. Jeffrey Kahn, Ph.D., M.P.H. John Zaia, M.D.	

Tuesday, September 9, 2008 (continued)

	Ad hoc Reviewer:	Roberto Cattaneo, Ph.D., Mayo Clinic, Rochester, MN (via teleconference)	
	Tab 2517	Protocol	
	Tab 2518	Office of Biotechnology Activities (OBA) Summary OBA Letter to PIs on In-Depth RAC Review and Public Discussion Reviews from Drs. Fan, Kahn, Zaia, and Cattaneo PIs'/Sponsor's Response	
3:05 PM	Public Comment		
3:15 PM	BREAK		
3:30 PM	Discussion of Human Gene Transfer Protocol #0807-930: A Double- Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer's Disease		
	PI: Paul S. Aisen, M.D., University of California, San Diego, La Jolla, CA		
	RAC Reviewers:	Robyn Shapiro, J.D. Scott Strome, M.D. David Williams, M.D.	
	Ad hoc Reviewer:	Bradley T. Hyman M.D., Ph.D., Massachusetts General Hospital, Charlestown, MA	
	Tab 2519	Protocol	
	Tab 2520	OBA Summary OBA Letter to PI on In-Depth RAC Review and Public Discussion Reviews from Drs. Strome, Williams, and Hyman and Ms. Shapiro PI's/Sponsor's Response	
5:10 PM	Public Comment		

5:15 PM ADJOURNMENT

Wednesday, September 10, 2008

8:15 AM	AM Call to Order and Opening Remarks			
	Howard Federoff, M.D., Ph.D., Chair, NIH RAC			
8:20 AM	Minutes of the June 17-18, 2008, RAC Meeting			
	RAC Reviewers:	Jane Flint, Ph.D. Nikunj Somia, Ph.D.		
	Tab 2515 Minu	ttes of the June 17-18, 2008, RAC Meeting		
8:30 AM	Discussion of Human Gene Transfer Protocol #0807-932: A Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Intravenous Doses of ANZ-521 in Treatment-Naïve Hepatitis C Patients			
	PI: Eric TX	J. Lawitz, M.D., Alamo Medical Research, San Antonio,		
	RAC Reviewers:	Hildegund Ertl, M.D. Jeffrey Kahn, Ph.D., M.P.H. Lee-Jen Wei, Ph.D.		
	Tab 2521	Protocol		
	Tab 2522	OBA Summary OBA Letter to PI on In-Depth RAC Review and Public Discussion Reviews from Drs. Ertl, Kahn, and Wei PI's/Sponsor's Response		
10:10 AM	Public Comment			
10:20 AM	BREAK			
10:30 AM	Discussion of Human Gene Transfer Protocol #0807-931: A Phase I/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glycosidase (rAAV1-CMV-GAA Gene Vector) in Patients with Pompe Disease			
	-	J. Byrne, M.D., Ph.D., University of Florida, esville, FL		
	RAC Reviewers:	Jeffrey Bartlett, Ph.D. Eric Kodish, M.D. James Yankaskas, M.D., M.S.		

Wednesday, September 10, 2008 (continued)

	Ad hoc Reviewer:	Priya Kishnani, Ph.D., Duke University, Durham, NC (via teleconference)	
	Tab 2523	Protocol	
	Tab 2524	OBA Summary OBA Letter to PI on In-Depth RAC Review and Public Discussion Reviews from Drs. Bartlett, Kodish, Yankaskas, and Kishani PI's/Sponsor's Response	
12:10 PM	Public Comment		
12:20 PM	WORKING LUNCH		
12:40 PM	Food and Drug Administration (FDA) Regulatory Updates:		
	Foreign Trials for Investigational New Drugs		
	Presenter:	Donna Przepiorka, M.D., Ph.D., FDA, Rockville, MD	
	FDA Guidance on Current Good Manufacturing Practice for Phase I Trials		
	Presenter:	Daniel Takefman, Ph.D., FDA, Rockville, MD	
1:15 PM	Discussion of Human Gene Transfer Protocol #0807-923: Compassionate Trial of Nanocomplex Mediated GNE Gene Replacement in Hereditary Inclusion Body Myopathy-2		
	PI: John J. Nem Dallas, TX	unaitis, M.D., Mary Crowley Cancer Research Centers,	
	RAC Reviewers:	Howard Federoff, M.D., Ph.D. Robyn Shapiro, J.D.	
	Tab 2525	Protocol	
	Tab 2526	OBA Summary OBA Letter to PI on In-Depth RAC Review and Public Discussion Reviews from Dr. Federoff and Ms. Shapiro PI's/Sponsor's Response	
2:30 PM	Public Comment		

Wednesday, September 10, 2008 (continued)

2:45 PM	Discussion of Single Subject Human Gene Transfer Trials ("Compassionate Use") and the Role of the RAC		
	Presenter:	Jacqueline Corrigan-Curay, M.D., J.D.	
	Moderator:	Howard Federoff, M.D., Ph.D.	
3:45 PM	Public Commer	nt	
3:55 PM	BREAK		
4:05 PM	Followup on <i>NIH Guidelines for Research Involving Recombinant DNA Molecules</i> : Noncontemporary Influenza and Highly Pathogenic Avian Influenza		
	Presenter:	Joseph Kanabrocki, Ph.D.	
4:50 PM	Public Commer	ıt	
5:00 PM	ADJOURNMENT		